Biomx Ltd (PHGE) Stock Price, Quote & News

Company Profile

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by P...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 7 2394 2377

Website: www.biomx.com

Address:

22 Einstein Street, Floor 4, Ness Ziona, Israel

WallStWireAds Jun. 26 at 12:40 PM

$PHGE https://venture-block.com/this-13m-biotech-has-40m-in-pentagon-funding-heres-why-biomx-could-be-biotechs-best-kept-secret/

0 · Reply

WallStWireAds Jun. 24 at 3:14 PM

$PHGE

0 · Reply

YasirTrades Jun. 23 at 2:12 PM

GLMD: $1 stock with $12+ book, $20M+ cash, no dilution, and a GLP-1 catalyst any week now. Last run hit $24. This is what a pressure cooker looks like before it blows. $PHGE $TTOO $SNTI $MBOT ..

0 · Reply

Docbrooks Jun. 23 at 3:13 AM

$PHGE Overnight spread is 13%. Tomorrow will be interesting.

0 · Reply

theCATALYST Jun. 20 at 3:31 PM

$PHGE compelling trade thesis and long term technicals for a multi-bagger. Not making a long post about this one, but if you ignore the hyperbolic title of the article and read the results…you’ll begin to see the story https://thefinanceherald.com/wall-street-sees-3000-upside-as-this-13m-biotech-tackles-medicines-superbug-crisis-phge/

0 · Reply

YasirTrades Jun. 20 at 2:27 AM

GLMD is the sleeper play of the year. Trading below cash, zero debt, real biotech catalysts ahead, and a float that already pushed it to $2.08. When eyes return, this could ignite fast. $PHGE $IMRN $VTAK $PRSO

0 · Reply

WallStWireAds Jun. 18 at 2:31 PM

$PHGE https://x.com/MonkofFinance/status/1935325985127223745

0 · Reply

WallStWireAds Jun. 18 at 2:01 PM

$PHGE $SLXN

0 · Reply

WallStWireAds Jun. 18 at 1:12 PM

$PHGE https://www.insideprecisionmedicine.com/topics/precision-medicine/91-days-later-biomxs-phage-fights-off-diabetic-bone-infection-in-phase-ii/

0 · Reply

Plain360 Jun. 17 at 11:22 PM

$JBIO, $NAK, $INDO, $PHGE and $HCTI are my green winners, pumped $PCSA , made some coin on $AZTR $SOND $BATL had these losers but only a few coins $ZBAI lost 8.00 $TXMD lost 3.00 still sitting on 10 put options for $WOLF exp in Sep at 7.00 (have these potatos since early march held too long and the WSJ article made me a loser.

0 · Reply

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

May 15, 2025, 4:57 PM EDT - 5 weeks ago

BiomX Inc. (PHGE) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 6:30 AM EDT - 6 weeks ago

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

May 8, 2025, 7:00 AM EDT - 7 weeks ago

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

Apr 1, 2025, 6:30 AM EDT - 3 months ago

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

Mar 31, 2025, 6:30 AM EDT - 3 months ago

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

Mar 25, 2025, 6:30 AM EDT - 3 months ago

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates

Mar 19, 2025, 12:35 PM EDT - 3 months ago

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Nov 14, 2024, 10:20 AM EST - 7 months ago

BiomX Inc. (PHGE) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 6:30 AM EST - 8 months ago

BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

Nov 12, 2024, 12:20 PM EST - 8 months ago

BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

Oct 15, 2024, 7:00 AM EDT - 9 months ago

BiomX Announces a Mandatory Unit Separation

Sep 18, 2024, 8:00 AM EDT - 10 months ago

BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference

Sep 4, 2024, 8:00 AM EDT - 10 months ago

BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 16, 2024, 10:55 AM EDT - 11 months ago

UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split

Aug 15, 2024, 12:03 PM EDT - 11 months ago

BiomX Inc. (PHGE) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 6:30 AM EDT - 11 months ago

BiomX Inc. Announces 1-for-10 Reverse Stock Split

Aug 15, 2024, 6:30 AM EDT - 11 months ago

BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates

Aug 8, 2024, 7:00 AM EDT - 11 months ago

BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024

Jul 31, 2024, 7:35 AM EDT - 11 months ago

Top 3 Health Care Stocks That May Explode In Q3

DXCM EW

Jul 29, 2024, 7:00 AM EDT - 11 months ago

BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Jul 10, 2024, 6:30 AM EDT - 1 year ago

BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock

May 30, 2024, 4:50 PM EDT - 1 year ago

BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

May 30, 2024, 7:00 AM EDT - 1 year ago

BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024

May 21, 2024, 10:25 AM EDT - 1 year ago

BiomX (PHGE) Q1 2024 Earnings Call Transcript

May 21, 2024, 6:30 AM EDT - 1 year ago

BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates

May 15, 2024, 7:00 AM EDT - 1 year ago

BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024

Apr 23, 2024, 8:00 AM EDT - 1 year ago

BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)

Apr 18, 2024, 8:00 AM EDT - 1 year ago

BiomX Announces the Appointment of Susan Blum to its Board of Directors

Apr 3, 2024, 12:26 PM EDT - 1 year ago

BiomX Inc. (PHGE) Q4 2023 Earnings Call Transcript

Apr 3, 2024, 6:30 AM EDT - 1 year ago

BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 27, 2024, 6:30 AM EDT - 1 year ago

BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024

Mar 18, 2024, 6:30 AM EDT - 1 year ago

BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing

Mar 6, 2024, 7:30 AM EST - 1 year ago

BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing

Jan 4, 2024, 8:00 AM EST - 1 year ago

BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis

Nov 30, 2023, 4:15 PM EST - 1 year ago

BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023

Nov 29, 2023, 6:30 AM EST - 1 year ago

BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

Nov 23, 2023, 7:43 AM EST - 1 year ago

BiomX: BX004 Phage Cocktail Part 2, Phase 1b/2a Clinical Results In Cystic Fibrosis Expected Any Day

Nov 14, 2023, 6:30 AM EST - 1 year ago

BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 27, 2023, 8:00 AM EDT - 1 year ago

BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference

Oct 18, 2023, 8:00 AM EDT - 1 year ago

BiomX Announces the Appointment of Edward L. Williams to its Board of Directors

Oct 4, 2023, 6:34 AM EDT - 1 year ago

BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

Sep 7, 2023, 9:00 AM EDT - 1 year ago

BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023

Sep 6, 2023, 4:05 PM EDT - 1 year ago

BiomX to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 9, 2023, 9:59 AM EDT - 2 years ago

BiomX Inc. (PHGE) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 6:30 AM EDT - 2 years ago

BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 2, 2023, 4:30 PM EDT - 2 years ago

BiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023

Jun 8, 2023, 5:00 PM EDT - 2 years ago

NYSE American Initiates Delisting Proceedings for BiomX Warrants

Jun 2, 2023, 4:15 PM EDT - 2 years ago

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of BiomX Inc. (PHGE.WS)

WallStWireAds Jun. 26 at 12:40 PM

$PHGE https://venture-block.com/this-13m-biotech-has-40m-in-pentagon-funding-heres-why-biomx-could-be-biotechs-best-kept-secret/

0 · Reply

WallStWireAds Jun. 24 at 3:14 PM

$PHGE

0 · Reply

YasirTrades Jun. 23 at 2:12 PM

GLMD: $1 stock with $12+ book, $20M+ cash, no dilution, and a GLP-1 catalyst any week now. Last run hit $24. This is what a pressure cooker looks like before it blows. $PHGE $TTOO $SNTI $MBOT ..

0 · Reply

Docbrooks Jun. 23 at 3:13 AM

$PHGE Overnight spread is 13%. Tomorrow will be interesting.

0 · Reply

theCATALYST Jun. 20 at 3:31 PM

0 · Reply

YasirTrades Jun. 20 at 2:27 AM

0 · Reply

WallStWireAds Jun. 18 at 2:31 PM

$PHGE https://x.com/MonkofFinance/status/1935325985127223745

0 · Reply

WallStWireAds Jun. 18 at 2:01 PM

$PHGE $SLXN

0 · Reply

WallStWireAds Jun. 18 at 1:12 PM

$PHGE https://www.insideprecisionmedicine.com/topics/precision-medicine/91-days-later-biomxs-phage-fights-off-diabetic-bone-infection-in-phase-ii/

0 · Reply

Plain360 Jun. 17 at 11:22 PM

0 · Reply

Plain360 Jun. 17 at 6:01 PM

$PHGE In at .3987

0 · Reply

WallStWireAds Jun. 16 at 11:54 PM

$PHGE https://www.benzinga.com/content/45964033/biomx-stock-could-soar-3000-as-this-10m-biotech-cracks-the-superbug-code-wall-street-says

0 · Reply

PenkeTrading Jun. 13 at 9:23 AM

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Biomx Inc. Is that bullish or bearish? $PHGE #Biomx #RsiOversold #NYSEMKT

1 · Reply

VentureBlock Jun. 12 at 1:10 PM

$PHGE

0 · Reply

BinSF Jun. 12 at 8:47 AM

$PHGE One would think the Biotech sector eventually needs to run if the game is to continue. But what do I know?

0 · Reply

JCH007 Jun. 6 at 8:21 PM

$PHGE Worth a shot down here. I'm in!

1 · Reply

WallStWireAds Jun. 6 at 2:11 PM

$PHGE https://thefinanceherald.com/wall-street-sees-3000-upside-as-this-13m-biotech-tackles-medicines-superbug-crisis-phge/

0 · Reply

BinSF Jun. 2 at 10:22 PM

$PHGE Buying this everyday down at these dumpster fire prices. Nervous nellies please keep selling me your shares!

0 · Reply

BinSF Jun. 2 at 10:19 PM

$PHGE

0 · Reply

GrandmaStonks Jun. 2 at 2:47 PM

$PHGE Just constant new lows

0 · Reply

BinSF May. 20 at 9:44 PM

$PHGE Just doing some light DD. $21.2m cash reserves while mktcp only 14m. While I see they are rockstars at burning cash, the IP seems worth way more than what the current stock price reflects. Phage therapy has significant research to show merit.

0 · Reply

JarvisFlow May. 16 at 11:00 AM

HC Wainwright & Co. updates rating for BiomX ( $PHGE ) to Buy, target set at 21 → 15.

0 · Reply

Market Cap	12.80M
Revenue (ttm)	0.00
Net Income (ttm)	-17.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	40,600
Avg Vol	149,026
Day's Range	N/A - N/A
Shares Out	26.18M
Stochastic %K	82%
Beta	1.43
Analysts	Strong Sell
Price Target	$15.00